logo

For the Inventor, By the Inventor

Evanston, IL, United States of America

Aptinyx Inc.


USPTO Granted Patents = 28

% Expired Patents = 3.6


Trademarks = 1

Forward Citations = 364

Loading Chart...
Loading Chart...

2 inventors (with patents filed for the assignee):

goldMedal M Amin Khan (28 out of 46 patents)

silverMedal John Adams Lowe, Iii (13 out of 83 patents)

bronzeMedal John A Iii Lowe (0 patent)

4.  Amin M Khan (0 patent)

5.  John A Iii Lowe (0 patent)


Core Competencies:
NMDA Receptor
Modulators
Spiro-lactam
Therapeutics
Neurology
Pharmacology
Drug Development
Bis-spiro-lactam
Neurotransmission
Clinical Applications
Cognition
Synaptic Plasticity

28 patents:

1. 11578072 - Spiro-lactam NMDA receptor modulators and uses thereof (2023-02-14),
2. 11530223 - Spiro-lactam NMDA receptor modulators and uses thereof (2022-12-20),
3. 11512051 - Spiro-lactam NMDA receptor modulators and uses thereof (2022-11-29),
4. 11427585 - Spiro-lactam NMDA modulators and methods of using same (2022-08-30),
5. 11376250 - Spiro-lactam NMDA receptor modulators and uses thereof (2022-07-05),
6. 11370790 - Spiro-lactam NMDA modulators and methods of using same (2022-06-28),
7. 11299495 - Spiro-lactam NMDA receptor modulators and uses thereof (2022-04-12),
8. 11077094 - Spiro-lactam NMDA receptor modulators and uses thereof (2021-08-03),
9. 11028095 - Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof (2021-06-08),
10. 10961189 - Spiro-lactam NMDA receptor modulators and uses thereof (2021-03-30),
11. 10918637 - Spiro-lactam NMDA receptor modulators and uses thereof (2021-02-16),
12. 10441572 - Spiro-lactam NMDA receptor modulators and uses thereof (2019-10-15),
13. 10441571 - Spiro-lactam NMDA receptor modulators and uses thereof (2019-10-15),
14. 10316041 - Spiro-lactam NMDA receptor modulators and uses thereof (2019-06-11),
15. 10273239 - Spiro-lactam NMDA receptor modulators and uses thereof (2019-04-30),
Company Overview
Aptinyx Inc. is a biopharmaceutical company based in Evanston, Illinois, focused on developing innovative therapies for neurological disorders. The company specializes in the discovery and development of novel compounds that modulate synaptic plasticity, a key mechanism underlying learning and memory. Aptinyx's research leverages advanced technologies to address unmet medical needs in conditions such as chronic pain, cognitive impairment, and other central nervous system disorders, aiming to improve patient outcomes through targeted treatment strategies.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

Aptinyx Inc. USPTO Patent Assignee Logo
28 Patents

#11 in Evanston, IL

#642 in Illinois

#12,013 in US

#23,285 in the World

Evanston, IL (US)
Evanston, IL, United States of America

Aptinyx Inc.

Forward Citations = 364

2 inventors:

goldMedal M Amin Khan (28 out of 46 patents)

silverMedal John Adams Lowe, Iii (13 out of 83 patents)

bronzeMedal John A Iii Lowe (0 patent)

4.  Amin M Khan (0 patent)

5.  John A Iii Lowe (0 patent)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Aptinyx Inc.. Retrieved from https://idiyas.com/company/aptinyx

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…